EXPERIENCE
LIFE WITHOUT
LIMITS.

Our Mission

Reprieve Cardiovascular is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). The company’s Reprieve technology is being investigated as an innovative fluid management therapy. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enable improved cardiac care, as well as, be instrumental in the decongestion of ADHF patients. Reprieve Cardiovascular is led by a seasoned management team with extensive experience in the medical device industry.

How it Works

Learn More

Heart Failure

Heart failure is a chronic, progressive disease that occurs when the heart cannot pump enough oxygen-rich blood to circulate throughout the body. The reduced blood flow sets into motion a complicated sequence of responses originating from the kidneys. Blood pressure increases, the kidneys retain water and sodium, and fluids build up in the extremities of the body, lungs, and other organs. At the same time, fluid volume and pressure in arterial space decreases. Patients may have 30 to 40 liters of excess fluid in their body, but their intravascular space may be fluid depleted.

Every year, over 1 million patients in the United States are hospitalized due to heart failure. 1 in 4 are readmitted within 30 days. 50% of patients who are diagnosed with heart failure die within 5 years of diagnosis, and 1 in 9 deaths in the United States lists heart failure as a contributing cause. It is estimated that CHF currently leads to 10’s of billions of dollars in healthcare spending and is predicted to grow to 53 billion dollars by 2030.

ADHF is a sudden onset of heart failure symptoms, which typically include difficulty breathing (dyspnea), swelling in the extremities, and fatigue. Current treatment for ADHF includes diuretic therapy that aims to restore healthy fluid levels in the kidneys and throughout the body. Diuretic therapy can be unpredictable and lose effectiveness as a patient’s condition worsens. In some patients, diuretics can trigger a condition called “diuretic resistance,” which blunts the function of diuretics and can worsen the severity of fluid overload, potentially resulting in acute kidney injury. Reprieve-Guided Diuretic Therapy is designed to allow clinicians to increase the dose of diuretics without increasing the risk of diuretic resistance, enabling safe and effective removal of excess fluid from ADHF patients and alleviation of symptoms.

Guided Diuretic Therapy

Reprieve Cardiovascular’s Guided Diuretic Therapy is designed to manage fluids during diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF), and may relieve a number of symptoms related to this condition. The therapy has the potential to enable precise and predictable management of a patient’s fluid levels, guarding against dangerous fluid imbalances and enabling better control over diuretic therapy thus increasing the diuretic efficiency a patient experiences. Potential benefits include speeding decongestion while protecting core organ function, lessening of symptoms of CHF, such as shortness of breath, ascites, and swelling, reduced time in hospital, reduced readmission rates, and a better quality of life for the patient.

Reprieve Cardiovascular technology is based on the RenalGuard Platform, which was originally developed to protect the kidneys of patients undergoing catheter-based interventional procedures. To-date, over 20,000 patients have been treated worldwide, including over 1,800 patients enrolled in published clinical studies utilizing this platform.

Events

Reprieve Cardiovascular will be featured at the following conferences. If you are attending and would like to meet with us, please contact info@reprievecardio.com.

 

Date Conference Location
15-17 Sept. 2018 Heart Failure Society of America Nashville, TN USA
2-4 Dec. 2018 ICI 2018 Jerusalem, Israel
14-15 Dec. 2018 Devices in Heart Failure
(D-HF)
Frankfurt, Germany
Events

Reprieve Cardiovascular will be featured at the following conferences. If you are attending and would like to meet with us, please contact info@reprievecardio.com.

15-17 Sept. 2018
Heart Failure Society of America (Nashville, TN USA)

2-4 Dec. 2018
ICI 2018 (Jerusalem, Israel)

14-15 Dec. 2018
Devices in Heart Failure (D-HF) (Frankfurt, Germany)

Meet the Team

Our management team is comprised of experienced talented professionals with a proven track record of successfully bringing innovative medical device technology to market.

J. Alex Martin

J. Alex Martin

Chairman of the Board

Jim Dillon

Jim Dillon

President and Chief Executive Officer

Howard Levin

Howard Levin

Chief Medical Officer

Andrew Halpert

Andrew Halpert

Chief Technology Officer

Gregory W. Mann

Gregory W. Mann

Managing Director, Chief Business and Financial Officer

Kenneth J. Luppi

Kenneth J. Luppi

Vice President, Operations

J. Alex Martin

J. Alex Martin

Chairman of the Board

Jim Dillon

Jim Dillon

President and Chief Executive Officer

Howard Levin

Howard Levin

Chief Medical Officer

Andrew Halpert

Andrew Halpert

Chief Technology Officer

Gregory W. Mann

Gregory W. Mann

Managing Director, Chief Business and Financial Officer

Kenneth J. Luppi

Kenneth J. Luppi

Vice President, Operations

Get in Touch

For more information on our solution or to inquire about investment opportunities, please complete the form below. We look forward to hearing from you.

  • This field is for validation purposes and should be left unchanged.
WE WOULD LOVE TO HEAR FROM YOU!

Reprieve Cardiovascular, Inc.
459 Fortune Boulevard
Milford, MA 01757
Tel: 508.541.8800
E-mail: info@ReprieveCardio.com

WE WOULD LOVE TO HEAR FROM YOU!

Reprieve Cardiovascular, Inc.
459 Fortune Boulevard
Milford, MA 01757
Tel: 508.541.8800
E-mail: info@ReprieveCardio.com

  • This field is for validation purposes and should be left unchanged.